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Aims:Contrastmedia-inducednephropathy (CIN) is associatedwith increasedmorbidity andmortality. The renal
endothelin system has been associated with disease progression of various acute and chronic renal diseases.
However, robust data coming from adequately powered prospective clinical studies analyzing the short and
long-term impacts of the renal ET system in patients with CIN are missing so far. We thus performed a prospec-
tive study addressing this topic.
Main methods:We included 327 patients with diabetes or renal impairment undergoing coronary angiography.
Blood and spot urinewere collected before and 24 h after contrastmedia (CM) application. Patientswere follow-
ed for 90 days for major clinical events like need for dialysis, unplanned rehospitalization or death.
Key ﬁndings: The concentration of ET-1 and the urinary ET-1/creatinine ratio decreased in spot urine after CM ap-
plication (ET-1 concentration: 0.91 ± 1.23 pg/ml versus 0.63 ± 1.03 pg/ml, p b 0.001; ET-1/creatinine ratio:
0.14 ± 0.23 versus 0.09 ± 0.19, p b 0.001). The urinary ET-1 concentrations in patients with CIN decreased
signiﬁcantly more than in patients without CIN (−0.26 ± 1.42 pg/ml vs.−0.79 ± 1.69 pg/ml, p = 0.041),
whereas the decrease of the urinary ET-1/creatinine ratio was not signiﬁcantly different (non-CIN patients:
−0.05 ± 0.30; CIN patients:−0.11 ± 0.21, p = 0.223). Urinary ET-1 concentrations as well as the urinary
ET-1/creatinine ratio were not associated with clinical events (need for dialysis, rehospitalization or death)
during the 90 day follow-up after contrast media exposure. However, the urinary ET-1 concentration and
the urinary ET-1/creatinine ratio after CM application were higher in those patients who had a decrease
of GFR of at least 25% after 90 days of follow-up.
Signiﬁcance: In general the ET-1 system in the kidney seems to be down-regulated after contrast media ap-
plication in patients with moderate CIN risk. Major long-term complications of CIN (need for dialysis, rehos-
pitalization or death) are not associated with the renal ET system.© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/ .0/).3Introduction
Besides chronic renal failure there are also studies indicating that the
renal ET systemmight play a role in the pathogenesis of acute kidney in-
jury. Ischemia–reperfusion injury by bilateral clamping of the renal ped-
icles for 30 min causes an up-regulation of ET-1 and the ETA receptor in
wild-type animals with associated vascular and tubular injuries at 24 h
after ischemia–reperfusion injury. Both measures were attenuated in
animals with a deletion of vascular endothelial cell ET-1 genecience, University of Potsdam,
. This is an open access article underexpression suggesting that the renal ET system might be involved in
the pathogenesis of acute kidney injury (AKI) (Arﬁan et al., 2012). Evi-
dence that ET-1 may alter the intrarenal microcirculation in AKI — so
supporting ET blockers as a potential therapeutic strategy in AKI —
comes from a model of endotoxin-induced AKI. In this case, treatment
with an ETA receptor antagonist attenuated the reduction in medullary
blood ﬂow independent of changes in systemic blood pressure and
total renal blood ﬂow (Fenhammar et al., 2011). Given that ET-1 has ef-
fects beyond simply altering vascular tone, other factors may mediate
the beneﬁts of ET receptor blockade. These include a reduction in oxida-
tive stress and inﬂammation (Arﬁan et al., 2012; Gulmen et al., 2009).
Thus the renal ET system might be critical in the control of microcircu-
lation and oxidative stress during AKI and hence modulation AKI
outcome.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ .0/).3
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Fig. 1. Study design.
Table 1
Baseline characteristics of the cohort.
Patients' characteristics N 327 (100%)
Female (%) / male (%) 75 (22.9%) / 252 (77.1%)
Age (±SD) years 68.94 (±9.73)
Body mass index (±SD) kg/m2 29.04 (±5.51)
CM-volume (±SD) ml 113.46 (±57.13)
Baseline creatinine (±SD) mg/dl 1.24 (±0.45)
Baseline cystatin c (±SD) mg/l 1.15 (±0.46)
Baseline urinary ET-1 pg/ml 0.91 (±1.23)
Baseline GFR ml/min/1.73 m2 64.51 (±21.33)
Diabetes mellitus (%) 175 (53.5%)
Congestive heart failure (%) 86 (26.3%)
Coronary artery disease (%) 235 (71.9%)
Hypertension (%) 290 (88.7%)
Anemia (%) 90 (27.5%)
Hydration (%) 177 (54.1%)
Smoking (%) 50 (15.3%)
Diuretics (%) 206 (63.0%)
ACE inhibitors (%) 178 (54.4%)
ARB (%) 107 (32.7%)
CM: contrast media, GFR: glomerulary ﬁltration rate according to the MDRD formula, SD:
standard deviation, ACE: angiotensin converting enzyme, ARB: angiotensin receptor
blocker.
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caused by iodinated radiocontrast media. This earnest complication
after contrast media application causes about 10% of all in-hospital AKI
(Nash et al., 2002). CIN goes along with a reduction of the glomerulary
ﬁltration rate (GFR) and an increase of the renal function marker creat-
inine and cystatin c, respectively. But there is no standardized deﬁnition
of CIN yet (Barrett, 1994). In clinical studies there is a wide range in the
change of the concentration (Cochran et al., 1983; Byrd and Sherman,
1979; Gomes et al., 1985) as well as in the observed time (Mason
et al., 1985; VanZee et al., 1978). In recent studies mostly the deﬁnition
“rise of 25% from baseline or 0.5 mg/dl within 48 h”was used. But also
an increase of cystatin c can be “a reliablemarker for the early diagnosis
and prognosis of contrast-induced acute kidney injury” (Briguori et al.,
2010). Meta-analyses of comparison of creatinine and cystatin c saw
an advantage to cystatin c for earlier detection of changes in the GFR
(Dharnidharka et al., 2002; Zhang et al., 2011). The combination of
bothmarkers to the deﬁnition of CINwas used, too (Poletti et al., 2007).
There are a large number of possible risk factors for CIN. The most
common ones are what Mehran et al. subsumed in a simple risk score
for CIN (Mehran et al., 2004). It includes increased creatinine levels or
impaired GFR, used volume of contrast media, diabetes mellitus, ane-
mia, age, congestive heart failure, periprocedurally intra-aortic balloon
pump and hypotension. In addition also the kind of CM could be a risk
factor (Solomon et al., 2006). Combination of risk factors enhances the
risk of a CIN above 57% (Mehran et al., 2004).
Patients with CIN have a poorer prognosis. The risk of a complete
loss of kidney function and the necessity of a dialysis rises with the
risk of CIN (Mehran et al., 2004). Additional patients with CIN are at
risk of a higher rate of all-cause mortality (Rihal et al., 2002).
The pathogenesis of CIN is still unknown (Seeliger et al., 2012). The-
ories include direct damage of the endothelia (Hizoh et al., 1998;
Andersen et al., 1994; Schick and Haller, 1999), induction of apoptosis
(Fanning et al., 2002), medullar hypoxia (Heyman et al., 2008) and per-
turbation of the regulation of the renal blood ﬂow (Sendeski et al.,
2009). Currently there are only very few smaller studies analyzing the
renal ET system in humans after exposure to contrast media. We thus
analyzed in a large prospective clinical study the renal ET system before
and after exposure to contrast media due to coronary angiography and
followed the patients for 90 days for clinical events.
Method
Study population and protocol
In a prospective study from January 2010 to December 2011 we in-
cluded 327 patients with renal impairment (creatinine N 1.1 mg/dl)
or diabetes mellitus (predescribed or HbA1c N 6.4%) undergoing a cor-
onary angiography. Excluded were all patients without any inclusion
criteria or with terminal kidney disease. Patients, who didn't give or
weren't able to give their agreement were excluded, either. The design
of the study is illustrated in Fig. 1. The treatment of the patients was
not inﬂuenced in any case by this study. All patients got the triiodonatednon-ionic low-osmolar iobitridol (XENETIX® 350, Guerbet GmbH,
Sulzbach/Taunus, Germany) as contrast media. If patients have a higher
risk to develop CIN, the physician responsible for this patient gave 0.9%
saline solution i.v. with (500 ml before and two times 500 ml after CM
examination).Sample treatment and measurement
The samples were frozen at−80 °C the very same day. Before freez-
ing blood samples were centrifuged 5 min with 3000 rotates per
minutes and only the plasma was frozen. Creatinine was measured
according to the method of Jaffé. Cystatin c was measured by an
immunonephelometric method using polystyrene particles coated
with human cystatin c speciﬁc antibodies (SiemensHealthcareDiagnos-
tics Products GmbH, Marburg, Germany). For the measurement of ET-1
a Quantikine ELISA (DET100, R&D Systems, Minneapolis, USA) was
used. Its mean minimum detectable dose is 0.087 pg/ml. No signiﬁcant
cross-reactivity of this ELISA is detectable for Big Endothelin-1 (aa
16–38), Big Endothelin-2, Sarafotoxins S6b and-S6c. Endothelin-2
shows 23.4% cross-reactivity according to themanufacturer of the assay.Deﬁnition of endpoints
CINwas deﬁned as an increase of creatinine of 25% or 0.5 mg/dl from
the baseline within 48 h or an increase of cystatin c of 25% from the
baseline within 24 h. Death is the subsumption of death of all causes.
The endpoint dialysis is deﬁned as every dialysis in the following
three months after CM application. Non-elective hospitalization is
Table 2
ET-1 before and 24 h after contrast media application.
ET-1 before ET-1 24 h after Change of ET-1
N Mean (±SD) p N Mean (±SD) p N Mean (±SD) p
Whole cohort 327 0.91 (±1.23) 313 0.63 (±1.03) 300 −0.33 (±1.42)
CIN No 255 0.91 (±1.19) 0.167 244 0.68 (±1.14) 0.236 239 −0.26 (±1.42) 0.041
Yes 38 1.21 (±1.75) 39 0.46 (±0.45) 37 −0.79 (±1.69)
Dialysis No 277 0.92 (±1.23) 0.431 265 0.60 (±0.97) 0.400 254 −0.38 (±1.36) 0.167
Yes 12 0.64 (±0.50) 11 0.85 (±1.49) 11 0.20 (±1.58)
Non-elective hospitalization No 237 0.83 (±1.03) 0.082 229 0.58 (±0.92) 0.522 221 −0.30 (±1.19) 0.176
Yes 48 1.32 (±1.84) 44 0.68 (±1.31) 42 −0.74 (±2.04)
Death No 279 0.92 (±1.23) 0.255 268 0.61 (±1.01) 0.810 257 −0.37 (±1.39) 0.343
Yes 9 0.46 (±0.28) 8 0.52 (±0.65) 8 0.10 (±0.54)
Decrease of GFR of≥25% (90 days) No 209 0.87 (±1.14) 0.671 200 0.55 (±0.91) 0.036 197 −0.35 (±1.25) 0.920
Yes 22 1.30 (±1.88) 20 1.27 (±1.92) 17 −0.52 (±2.14)
ET-1: urinary endothelin, uCr: urinary creatinine, CIN: contrast-induced nephropathy, GFR: glomerulary ﬁltration rate according to the MDRD formula, SD: standard deviation.
442 F. Heunisch et al. / Life Sciences 118 (2014) 440–445every hospital stay for any reason, which was not preplanned at study
entry.
Statistical analyses
The statistical analyses were made with SPSS 20 (IBM® SPSS® Sta-
tistics IBM Cooperation, Armonk, USA). Differences among the bio-
markers were estimated with Student's t-test for independent or t-test
for dependent variables.
Results
Details of the study population are shown in Table 1. There was no
difference in the ET-1 concentration at any time between groups with
diabetes mellitus, congestive heart failure, coronary artery disease, hy-
pertension, hydration or smoking and the groupswithout these risk fac-
tors (p N 0.05 for all).
The concentration of ET-1 and the urinary ET-1/creatinine ratio
decreased in spot urine after CM application (ET-1 concentration:
0.91 ± 1.23 pg/ml versus 0.63 ± 1.03 pg/ml, p b 0.001; ET-1/
creatinine ratio: 0.14 ± 0.23 versus 0.09 ± 0.19, p b 0.001). The
urinary ET-1 concentrations in patients with CIN decreased signif-
icantly more than in patients without CIN (−0.26 ± 1.42 pg/ml
vs. −0.79 ± 1.69 pg/ml, p = 0.041), whereas the decrease of the
urinary ET-1/creatinine ratio was not signiﬁcantly different (non-CIN
patients:−0.05 ± 0.30; CIN patients:−0.11 ± 0.21, p = 0.223). Uri-
nary ET-1 concentrations as well as the urinary ET-1/creatinine ratio
were not associated with clinical events (need for dialysis, rehospitali-
zation or death) during the 90 day follow-up after contrastmedia expo-
sure (see also Tables 2 and 3). The concentration of ET-1 and the urinary
ET-1/creatinine ratio in spot urine 24 h after CM application were,Table 3
ET-1/urinary creatinine ratio before and 24 h after contrast media application.
ET-1/uCr ratio before
N Mean (±SD) p
Whole cohort 326 0.14 (±0.23)
CIN No 254 0.14 (±0.25) 0.526
Yes 38 0.17 (±0.24)
Dialysis No 276 0.14 (±0.24) 0.263
Yes 12 0.22 (±0.21)
Non-elective hospitalization No 236 0.14 (±0.24) 0.276
Yes 48 0.18 (±0.22)
Death No 278 0.14 (±0.24) 0.950
Yes 9 0.14 (±0.19)
Decrease of GFR* of ≥25% (90 days) No 208 0.14 (±0.26) 0.387
Yes 22 0.20 (±0.25)
ET-1: urinary endothelin, uCr: urinary creatinine, CIN: contrast-induced nephropathy, GFR: glo
dependent variables.however, higher in those patients who had a decrease of GFR of at
least 25% after 90 days of follow-up (Tables 2 and 3).
Discussion
This prospective study with 327 participants showed a signiﬁcant
decrease of the urinary endothelin concentration as well as the urinary
ET-1/creatinine ratio after CM application. Death (all cause mortality),
need for permanent or transient dialysis or rehospitalization during
the follow-up of 90 days after CM application was not associated with
urinary ET-1 concentrations — neither before nor after CM exposure.
The urinary ET-1 concentration and the urinary ET-1/creatinine ratio
after CM application, however, were higher in those patients who had
a decrease of GFR of at least 25% after 90 days of follow-up.
Urinary endothelin concentrations in humans after CM application
Few studies analyzed ET-1after CM application yet. An overview is
shown in Table 4. The total number of patients analyzed is far less
than the number of patients in our study. Ulas et al. (2013). showed
an increase in the urinary as well as in the plasma ET-1 concentrations
in only 78 patients. It is of note that the applied contrast media volume
was much higher in this study as compared to our study (192 ml vs.
113 ml). However, CM volume matters. This was shown by Clark et al.
(1997). They divided their patients into two groups. One got less than
150 ml, the other more than 150 ml CM. Only the group with more
than 150 ml had an increase of the ET-1 level. In the small study by
Fujisaki et al. (2003) about 100 ml CM were used. They studied two
groups, one with normal creatinine levels, the other one with very
high levels (2.5 ± 0.5 mg/dl (mean ± SEM)). Only the group with
poor renal function had an increase of urinary ET-1 concentrations.ET-1/uCr ratio 24 h after Change of ET-1/uCr ratio
N Mean (±SD) p N Mean (±SD) p
312 0.09 (±0.19) 300 −0.06 (±0.28) b0.001*
244 0.10 (±0.21) 0.247 239 −0.05 (±0.30) 0.223
38 0.06 (±0.08) 37 −0.11 (±0.21)
264 0.08 (±0.15) 0.323 254 −0.07 (±0.27) 0.590
11 0.24 (±0.52) 11 0.01 (±0.45)
228 0.08 (±0.18) 0.504 221 −0.06 (±0.28) 0.518
44 0.10 (±0.20) 42 −0.09 (±0.24)
267 0.08 (±0.15) 0.465 257 −0.07 (±0.27) 0.083
8 0.25 (±0.60) 8 0.10 (±0.42)
200 0.07 (±0.14) 0.002 197 −0.07 (±0.29) 0.664
19 0.20 (±0.30) 17 −0.06 (±0.30)
merulary ﬁltration rate according to the MDRD formula, SD: standard deviation, *test for
Table 4
Overview over human studies with endothelin measurements after CM application.
Study N Baseline creatinine
[mg/dl]
Used CM CM volume
[ml]
Endothelin measurements Kind of samples Changes of endothelin
concentration (plasma/urine)
Clark et al. (1997) 7 (with high doses) 0.9 ± 0.1a Iopamidol (non-ionic, low osmolar)
or
Diatrizoate meglumine (ionic, high osmolar)
155 ± 2a Before and 15 min after angiography Plasma +/?
12
(with low doses)
1.1 ± 0.04a 82 ± 11a 0/?
8 (with renal failure and/or DM) 2.12 ± 0.3a 112 ± 15a +/?
Fujisaki et al. (2003) 6 (with renal impaired function) 2.5 ± 0.5a ? 98 ± 18a Before and 1, 2 and 3 days after CM
examination
Plasma and urine 0/+
6 (controls) 0.8 ± 0.1a 100 ± ?a 0/0
Simon et al. (2003) 11 ? Iopromid (non-ionic, low osmolar) 70–100 ml Before and 30 min after cardiac catheter Plasma 0/?
Chai et al. (2010) 40 with CAD ? (without renal failure) ? ? Before and 1, 2 and 3 days after CM
examination
Plasma +/?
40 controls ?/?
Ulas et al. (2013) 78 0.76 ± 0.12b Iobitridol (non-ionic, low osmolar) 192 ± 78b Before and 24 h after PCI Plasma and urine +/+
N: number of participants of the study, CM: contrast media, DM: diabetes mellitus, CAD: coronary artery disease, PCI: percutaneous coronary intervention, +: signiﬁcant increase, 0: no signiﬁcant change.
a Mean ± standard error of the mean.
b Mean ± standard deviation.
Table 5
Overview over animal studies testing ET receptor blockers in CM administration.
Study Model Used CM/medication for CIN Read out Kind of ET-1 blockade Effect of ET-1 blockade
Cantley et al. (1993) Rats Iothalamate (ionic high-osmolar CM),
indomethacin
Renal blood ﬂow, urine ﬂow rate CP170687 (non-selective) Can't prevent drop of renal blood ﬂow in normal rats, urine ﬂow like
placebo
Brooks and DePalma (1996) Dogs Diatrizoate (ionic high-osmolar CM),
indomethacin
Renal blood ﬂow, renal resistance SB209670 (non-selective) Abolishes the increase of the renal resistance and decrease of renal blood
ﬂow
Bird et al. (1996) Rats Iopamidol (non-ionic low-osmolar CM),
indomethacin, L-NAME
GFR, RPF, diuresis, necrosis SB209670 (non-selective), BMS-182,874
(ET-A receptor antagonist)
GFR less reduced, urinary ﬂow reduced, RPF without change, less morpho
logic necrosis, selective and non-selective blockade equivalent
Pollock et al. (1997) Rats Diatrizoate (ionic, high-osmolar CM),
(Indomethacin, L-NAME)
Protein excretion, plasma creatinine A-127722 (ET-A receptor antagonist) Reduction of protein excretion and plasma creatinine
Liss et al. (2003) Rats Iopromide (non-ionic, low-osmolar CM), Renal CBF, OMBF, pO2 BQ123 (ET-A receptor antagonist),
BQ788 (ET-B receptor antagonist)
No effect on CBF and OMBF, less reduction of pO2 with BQ123
CM: contrast media, ET: endothelin, MAP: mean arterial blood pressure, L-NAME: N-nitro-L-arginine-methylester, ET: endothelin, GFR: glomerulary ﬁltration rate. RPF: renal plasma ﬂow, CBF: cortical blood ﬂow, OMBF: outer medullary blood ﬂow:
pO2: outer medullary oxygen tension.
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444 F. Heunisch et al. / Life Sciences 118 (2014) 440–445Thus differences in applied CM volume and degree of preexisting renal
failure might explain our ﬁndings. There is obviously a critical CM vol-
ume threshold. Above this threshold, CM seems to be directly toxic to
the kidney and ET-1 rises. If the patients get less volume, only CM relat-
ed hemodynamic effects occur. CM are for example osmotic diuretics
and hence might cause transient hypotension contributing to the path-
ogenesis of CIN.
Urinary ET-1 and 90-day outcome after CM exposure
In our study hard endpoints such as death (all causemortality), need
for permanent or transient dialysis or rehospitalization during the
follow-up of 90 days after CM application was not associated with uri-
nary ET-1 concentrations — neither before nor after CM exposure. Yip
et al. (2005) investigated 186 patients with ST-elevated myocardial in-
farction undergoing percutaneous coronary interventions. These 186
patients were divided in two groups, dependent on their endothelin
level in the plasma. In addition these two groups vary in age, reperfu-
sion time and the incidence of the left ventricular ejection fraction. Pa-
tients with higher endothelin concentration (older, higher perfusion
time and less LVEF) had a highermortalitywithin 30 day μs after the in-
tervention. Unfortunately there was no information about the kidney
function of these patients. Nevertheless, this study showed a positive re-
lationship between the endothelin levels, risk factors and themortality.
Most likely, patients in this study were sicker — see above. This study
rather describes the relationship between an activated ET system and
mortality due to ST-elevatedmyocardial infarction then the relationship
between CM exposure and death. The leading event was the ST-elevat-
ed myocardial infarction in this study. This study is thus not a real CIN
study.
The decrease of both urinary ET-1 as well as the urinary ET-1/
creatinine ratio in the entire study population in our study ﬁts very
well with a recent clinical trial. In this prospective placebo controlled
clinical studyWang et al. (2000) investigated 158 patients with chronic
renal insufﬁciency and undergoing cardiac angiography and they were
randomized to receive either a mixed endothelin A and B receptor an-
tagonist, SB 290670, or placebo. The primary end point was the mean
change in serum creatinine concentration from baseline at 48 h; the
secondary end point was the incidence of radiocontrast nephrotoxicity,
deﬁned as an increase in serum creatinine of≥0.5 mg/dl (44 μmol/l) or
≥25% from baseline within 48 h of radiocontrast administration. The
mean increase in serum creatinine 48 h after angiography was higher
in the SB 209670 than in the placebo group. The incidence of
radiocontrast nephrotoxicity was also higher in the SB 209670 group
(56%) compared with placebo (29%, p = 0.002). This negative effect
of SB 209670 was apparent in both diabetic and non-diabetic patients.
Thus, blocking the ET system was harmful after CM exposure. This ﬁts
to a certain extent to the observation that patients have in our study.
Both blocking the ET systemwith ET receptor antagonists as well as re-
duced excretion of ET after CMmight be due to hemodynamic changes
after CM exposure in terms of blood pressure reduction. A fall in blood
pressure, however, increases the risk of CIN. This hypothesis needs for
sure be tested in further studies. Once again, this needs to be tested in
future studies.
It is of note in this context that there are a couple of promising
animal studies suggesting that blockade of ET receptors — either with
ETA selective agents or combined ETA/ETB receptor antagonists might
be useful to prevent CIN, see Table 5. These preclinical studies were
the basic for the abovementioned clinical study. It is important to
know in this context that a long list of drugs including selective and
non-selective ET receptor blockers work in animal models of various
types of acute renal failure— however, none of these drugswas ever ap-
proved from European or US authorities. This indicates that animal
models in the case of acute renal failure are of very limited clinical
value and were so far not helpful to develop a drug to prevent CIN.
Why these models are of such a limited translational value is poorlyunderstood.Maybe they are not close enough to the human situation: Pa-
tients getting CIN are typically elderly, have diabetes, heart failure, athero-
sclerosis, and preexisting renal failure due to chronic renal failure. The
animal models are typically young rodents without any co-morbidity.
Renal failure is induced in these models with pharmacological tool such
as indomethacin etc. These animal models are obviously far away from
thehuman situation. It is thus no surprise that data coming from these ex-
periments cannot be translated successfully to the human situation. We
urgently need good translational animal models of CIN.
Our clinical study showed that the urinary ET-1 concentration and
the urinary ET-1/creatinine ratio after CM application were higher in
those patients who had a decrease of GFR of at least 25% after 90 days
of follow-up —means the activations of the renal ET system after con-
trastmedia-induced AKI related long-term chronic alterations of kidney
function. This ﬁts nicely to a recent animal study ischemia-induced AKI
in rats showing that long-term activation after ischemic AKI leads to
chronic renal failure (Zager et al., 2013).
This study is the by far the largest clinical prospective observational
study in the ﬁeld. We presented short term outcomes (CIN) and long-
termoutcomes such as change ofGFR after 3 months, death, need for di-
alysis and rehospitalization during follow-up of 90 days in relationship to
urinary ET-1 concentrations as well as the urinary ET-1/creatinine ratio
before and 24 h after contrast media exposure. Given the unexpected
ﬁnding of a signiﬁcant decrease of the urinary endothelin concentration
as well as the urinary ET-1/creatinine ratio after CM application, this
study needs to be replicated in an independent second equally sized clin-
ical study.
We need to acknowledge that it is a clear study limitation that we
did not measure plasma ET-1 concentrations.
Conclusion
Urinary ET-1 and the urinary ET-1/creatinine ratio decrease after CM
application. There was no obvious relationship between ET-1 levels and
hard outcome such as death or need for dialysis after three months of
follow-up. Only a decrease of GFR N 25% after 90 days of follow-up
was associated with higher urinary ET-1 concentrations as well as ET-
1/creatinine ratios.
Conﬂict of interest
None of the authors has a conﬂict of interest with regard to this paper.
References
Arﬁan N, Emoto N, Vignon-Zellweger N, Nakayama K, Yagi K, Hirata K. ET-1 deletion
from endothelial cells protects the kidney during the extension phase of
ischemia/reperfusion injury. Biochem Biophys Res Commun 2012;425:443–9.
http://dx.doi.org/10.1016/j.bbrc.2012.07.121.
Briguori C, Visconti G, Rivera NV, Focaccio A, Golia B, Giannone R, et al. Cystatin C and
contrast-induced acute kidney injury. Circulation 2010;121:2117–22. http:
//dx.doi.org/10.1161/CIRCULATIONAHA.109.919639.
Cantley LG, Spokes K, Clark B, McMahon EG, Carter J, Epstein FH. Role of endothelin and
prostaglandins in radiocontrast-induced renal artery constriction. Kidney Int
1993;44:1217–23.
Fenhammar J, Andersson A, Forestier J, Weitzberg E, Sollevi A, Hjelmqvist H, et al.
Endothelin receptor A antagonism attenuates renal medullary blood ﬂow
impairment in endotoxemic pigs. PloS one 2011;6:e21534. http://dx.doi.org/
10.1371/journal.pone.0021534.
Fujisaki K, Kubo M, Masuda K, Tokumoto M, Hirakawa M, Ikeda H, et al. Infusion of
radiocontrast agents induces exaggerated release of urinary endothelin in patients
with impaired renal function. Clin Exp Nephrol 2003;7:279–83. http:
//dx.doi.org/10.1007/s10157-003-0246-y.
Gomes AS, Baker JD, Martin-Paredero V, Dixon SM, Takiff H, Machleder HI, et al. Acute
renal dysfunction after major arteriography. AJR Am J Roentgenol 1985;145:
1249–53. http://dx.doi.org/10.2214/ajr.145.6.1249.
Gulmen S, Kiris I, Narin C, Ceylan BG, Mermi B, Sutcu R, et al. Tezosentan reduces the renal
injury induced by abdominal aortic ischemia-reperfusion in rats. J Surg Res 2009;157:
e7-13. http://dx.doi.org/10.1016/j.jss.2008.08.011.
Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for
prediction of contrast-induced nephropathy after percutaneous coronary interven-
tion: development and initial validation. J Am Coll Cardiol 2004;44:1393–9. http:
//dx.doi.org/10.1016/j.jacc.2004.06.068.
445F. Heunisch et al. / Life Sciences 118 (2014) 440–445Poletti PA, Saudan P, Platon A, Mermillod B, Sautter AM, Vermeulen B, et al. I.v.
N-acetylcysteine and emergency CT: use of serum creatinine and cystatin C as
markers of radiocontrast nephrotoxicity. AJR Am J Roentgenol 2007;189:687–92.
http://dx.doi.org/10.2214/AJR.07.2356.
Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, et al. Incidence and prognostic
importance of acute renal failure after percutaneous coronary intervention. Circula-
tion 2002;105:2259–64.
Sendeski M, Patzak A, Pallone TL, Cao C, Persson AE, Persson PB, et al. Iodixanol,
constriction of medullary descending vasa recta, and risk for contrast
medium-induced nephropathy. Radiology 2009;251:697–704. http://dx.doi.org/
10.1148/radiol.2513081732.Ulas T, Buyukhatipoglu H, Dal MS, Kirhan I, Kaya Z, Demir ME, et al. Urotensin-II and
endothelin-I levels after contrast media administration in patients undergoing percu-
taneous coronary interventions. J Res Med Sci. 2013;18:205–9.
Wang A, Holcslaw T, Bashore TM, Freed MI, Miller D, Rudnick MR, et al.
Exacerbation of radiocontrast nephrotoxicity by endothelin receptor
antagonism. Kidney Int 2000;57:1675–80. http://dx.doi.org/10.1046/j.1523-
1755.2000.00012.x.
Yip HK, Wu CJ, Chang HW, Yang CH, Yu TH, Chen YH, et al. Prognostic value of cir-
culating levels of endothelin-1 in patients after acute myocardial infarction
undergoing primary coronary angioplasty. Chest 2005;127:1491–7. http:
//dx.doi.org/10.1378/chest.127.5.1491.
